{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=6",
    "query": {
      "intervention": "Mitoxantrone hydrochloride",
      "page": 6
    },
    "page_size": 10
  },
  "pagination": {
    "page": 6,
    "page_size": 10,
    "total_count": 176,
    "total_pages": 18,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=7&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Mitoxantrone+hydrochloride&page=5&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-12T23:55:07.182Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00003297",
      "title": "Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "topotecan hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 50,
      "start_date": "1997-12",
      "completion_date": "2001-01",
      "has_results": false,
      "last_update_posted_date": "2011-03-24",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003297"
    },
    {
      "nct_id": "NCT00002259",
      "title": "Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sarcoma, Kaposi",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Mitoxantrone hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lederle Laboratories",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002259"
    },
    {
      "nct_id": "NCT01564784",
      "title": "A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "inotuzumab ozogamicin",
          "type": "DRUG"
        },
        {
          "name": "FLAG (fludarabine, cytarabine and G-CSF)",
          "type": "DRUG"
        },
        {
          "name": "HIDAC (high dose cytarabine)",
          "type": "DRUG"
        },
        {
          "name": "cytarabine and mitoxantrone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2012-08-02",
      "completion_date": "2017-01-04",
      "has_results": true,
      "last_update_posted_date": "2019-01-09",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 96,
      "location_summary": "La Jolla, California • Los Angeles, California • Orange, California + 39 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01564784"
    },
    {
      "nct_id": "NCT00005802",
      "title": "Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "therapeutic hydrocortisone",
          "type": "DRUG"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": null,
      "start_date": "1999-06",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2010-04-02",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005802"
    },
    {
      "nct_id": "NCT00002598",
      "title": "Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "bone marrow ablation with stem cell support",
          "type": "PROCEDURE"
        },
        {
          "name": "radiation therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "1994-06",
      "completion_date": "2004-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-25",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002598"
    },
    {
      "nct_id": "NCT05848687",
      "title": "TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoblastic Leukemia"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Mitoxantrone",
          "type": "DRUG"
        },
        {
          "name": "PEG asparaginase",
          "type": "DRUG"
        },
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Vorinostat",
          "type": "DRUG"
        },
        {
          "name": "Mercaptopurine",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        },
        {
          "name": "Ziftomenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tanja Andrea Gruber",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "1 Year",
        "sex": "ALL",
        "summary": "Up to 1 Year"
      },
      "enrollment_count": 90,
      "start_date": "2023-11-03",
      "completion_date": "2033-12",
      "has_results": false,
      "last_update_posted_date": "2026-06-03",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 17,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Madera",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848687"
    },
    {
      "nct_id": "NCT02070458",
      "title": "Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "ixazomib",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10-08",
      "completion_date": "2017-08-15",
      "has_results": false,
      "last_update_posted_date": "2018-12-13",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 2,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02070458"
    },
    {
      "nct_id": "NCT00780104",
      "title": "Sirolimus in Combination With MEC in High Risk Myeloid Leukemias",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloid Leukemias",
        "AML",
        "Leukemia",
        "CML"
      ],
      "interventions": [
        {
          "name": "Rapamycin, Mitoxantrone, Etoposide, Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Rapamycin + MEC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2007-07",
      "completion_date": "2010-06",
      "has_results": false,
      "last_update_posted_date": "2019-07-12",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00780104"
    },
    {
      "nct_id": "NCT01839240",
      "title": "Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "azacitidine",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "mitoxantrone hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2012-06-06",
      "completion_date": "2019-08-16",
      "has_results": false,
      "last_update_posted_date": "2020-05-15",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01839240"
    },
    {
      "nct_id": "NCT01513603",
      "title": "Trial of Cladribine, Cytarabine, Mitoxantrone, Filgrastim (CLAG-M) in Relapsed Acute Lymphoblastic Leukemia",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Lymphoblastic Lymphoma",
        "Burkitts Leukemia/Lymphoma",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "CLAG-M",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York Medical College",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 50,
      "start_date": "2012-01",
      "completion_date": "2014-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-20",
      "last_synced_at": "2026-10-12T23:55:07.182Z",
      "location_count": 1,
      "location_summary": "Valhalla, New York",
      "locations": [
        {
          "city": "Valhalla",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01513603"
    }
  ]
}